Brian Dorsey - Aug 20, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Aug 20, 2024
Transactions value $
-$718,000
Form type
4
Date filed
8/21/2024, 06:51 PM
Previous filing
Aug 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $32K +50K +830.01% $0.64 56K Aug 20, 2024 Direct
transaction SPRY Common Stock Sale -$750K -50K -89.25% $15.00 6.02K Aug 20, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -50K -44.71% $0.00 61.8K Aug 20, 2024 Common Stock 50K $0.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.
F2 Immediately exercisable.